Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab

International Ophthalmology, 03/29/2012

Preoperative use of bevacizumab improved the 6–month visual outcome in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy and significantly reduced the occurrence of postoperative vitreous hemorrhage.

Print Article Summary Cat 2 CME Report